Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure Pharma’s CEO Martin Jönsson to present at Redeye’s Neurology Day
October 17, 2024
-
AlzeCure Pharma broadcasts live event about the phase II candidate ACD440 against neuropathic pain
October 10, 2024
-
AlzeCure’s abstract on ACD856’s anti-inflammatory effects to be presented at a leading Alzheimer’s conference
October 1, 2024